Evaluation of a Single Intravitreal Injection of 5-fluorouracil in Vitrectomy Cases

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 1989 Jan 1

PMID 2696670

Citations 7

Authors

G W Blankenship

Affiliations

Soon will be listed here.

Abstract

To evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) after pars plana vitrectomy, 51 eyes were followed in a prospective and randomized clinical trial in which, upon completion of surgery, 26 eyes received 10 mg intravitreal 5-FU and 25 control eyes did not receive 5-FU. The only possible sign of 5-FU toxicity was prolonged corneal epithelial edema. Visual acuities of 20/200 or better were obtained in 67% of the 5-FU group and 56% of the control group. Successful macular reattachment was obtained in 60% of the 5-FU group and 77% of the control group. None of the eyes in either group developed substantial intraocular proliferation or membranes. The findings indicate that a single 10-mg intravitreal injection of 5-FU is well tolerated without permanent toxic damage.

Citing Articles

Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.

Khanum B, Guha R, Sur V, Nandi S, Basak S, Konar A Eye (Lond). 2017; 31(9):1317-1328.

PMID: 28304388 PMC: 5601446. DOI: 10.1038/eye.2017.21.

Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy.

Ganekal S, Dorairaj S Saudi J Ophthalmol. 2014; 28(4):257-61.

PMID: 25473340 PMC: 4250514. DOI: 10.1016/j.sjopt.2014.03.005.

PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells.

Cai N, Dai S, Liu N, Liu L, Zhao N, Chen L Int J Ophthalmol. 2013; 5(6):675-80.

PMID: 23275900 PMC: 3530807. DOI: 10.3980/j.issn.2222-3959.2012.06.05.

Cystoid macular edema associated with oral antineoplastic agent s-1 in a patient with diabetic retinopathy.

Higashide T, Murotani E, Sugiyama K Case Rep Ophthalmol. 2012; 3(1):91-5.

PMID: 22548042 PMC: 3339688. DOI: 10.1159/000337491.

The clinical applications of fluorouracil in ophthalmic practice.

Abraham L, Selva D, Casson R, Leibovitch I Drugs. 2007; 67(2):237-55.

PMID: 17284086 DOI: 10.2165/00003495-200767020-00005.

References

Heuer D, Parrish 2nd R, Gressel M, Hodapp E, Palmberg P, Anderson D . 5-fluorouracil and glaucoma filtering surgery. II. A pilot study. Ophthalmology. 1984; 91(4):384-94. DOI: 10.1016/s0161-6420(84)34291-9. View

Blumenkranz M, Hartzer M, Hajek A . Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol. 1987; 105(3):396-9. DOI: 10.1001/archopht.1987.01060030116039. View

Blumenkranz M, Hernandez E, Ophir A, Norton E . 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 1984; 91(2):122-30. DOI: 10.1016/s0161-6420(84)34318-4. View

Glaser B . Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol. 1984; 102(9):1376-9. DOI: 10.1001/archopht.1984.01040031118037. View

Gressel M, Parrish 2nd R, Folberg R . 5-fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmology. 1984; 91(4):378-83. DOI: 10.1016/s0161-6420(84)34277-4. View

Faulborn J, Conway B, MACHEMER R . Surgical complications of pars plana vitreous surgery. Ophthalmology. 1978; 85(2):116-25. DOI: 10.1016/s0161-6420(78)35684-0. View

Lewis H, Abrams G, Williams G . Anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol. 1987; 104(6):607-13. DOI: 10.1016/0002-9394(87)90173-5. View

Blumenkranz M, Ophir A, CLAFLIN A, Hajek A . Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982; 94(4):458-67. DOI: 10.1016/0002-9394(82)90239-2. View

Mannis M, Sweet E, Lewis R . The effect of fluorouracil on the corneal endothelium. Arch Ophthalmol. 1988; 106(6):816-7. DOI: 10.1001/archopht.1988.01060130886046. View

10.

. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983; 90(2):121-5. DOI: 10.1016/s0161-6420(83)34588-7. View

11.

Hatchell D, McAdoo T, Sheta S, King 3rd R, Bartolome J . Quantification of cellular proliferation in experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1988; 106(5):669-72. DOI: 10.1001/archopht.1988.01060130731033. View

12.

Stern W, GuErin C, Erickson P, Lewis G, Anderson D, Fisher S . Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol. 1983; 96(1):43-51. DOI: 10.1016/0002-9394(83)90453-1. View

13.

Sebestyen J . Fibrinoid syndrome: a severe complication of vitrectomy surgery in diabetics. Ann Ophthalmol. 1982; 14(9):853-6. View

14.

Mallick K, Hajek A, Parrish 2nd R . Fluorouracil (5-FU) and cytarabine (ara-C) inhibition of corneal epithelial cell and conjunctival fibroblast proliferation. Arch Ophthalmol. 1985; 103(9):1398-402. DOI: 10.1001/archopht.1985.01050090150052. View

15.

Joondeph B, Peyman G, Khoobehi B, Yue B . Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg. 1988; 19(4):252-6. View

16.

Orr G, Tervaert D, Lean J . Aqueous concentrations of fluorouracil after intravitreal injection. Normal, vitrectomized, and silicone-filled eyes. Arch Ophthalmol. 1986; 104(3):431-4. DOI: 10.1001/archopht.1986.01050150133044. View

17.

Jarus G, Blumenkranz M, Hernandez E, Sossi N . Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology. 1985; 92(1):91-6. DOI: 10.1016/s0161-6420(85)34063-0. View

18.

Ruderman J, Welch D, Smith M, SHOCH D . A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol. 1987; 104(3):218-24. DOI: 10.1016/0002-9394(87)90407-7. View

19.

MACHEMER R . Massive periretinal proliferation: a logical approach to therapy. Trans Am Ophthalmol Soc. 1977; 75:556-86. PMC: 1311564. View